TR200705146T1 - Monoamin Yükselmesinin Engellenmesi - Google Patents

Monoamin Yükselmesinin Engellenmesi

Info

Publication number
TR200705146T1
TR200705146T1 TR2007/05146T TR200705146T TR200705146T1 TR 200705146 T1 TR200705146 T1 TR 200705146T1 TR 2007/05146 T TR2007/05146 T TR 2007/05146T TR 200705146 T TR200705146 T TR 200705146T TR 200705146 T1 TR200705146 T1 TR 200705146T1
Authority
TR
Turkey
Prior art keywords
monoamine
inhibition
elevation
mammals
methods
Prior art date
Application number
TR2007/05146T
Other languages
English (en)
Turkish (tr)
Inventor
Louis Mattiuz Edward
Taiwai Wong David
Joe Wheeler William
Sauer John-Michael
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200705146(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200705146T1 publication Critical patent/TR200705146T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR2007/05146T 2001-03-06 2002-02-20 Monoamin Yükselmesinin Engellenmesi TR200705146T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06

Publications (1)

Publication Number Publication Date
TR200705146T1 true TR200705146T1 (tr) 2008-02-21

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2007/05146T TR200705146T1 (tr) 2001-03-06 2002-02-20 Monoamin Yükselmesinin Engellenmesi

Country Status (35)

Country Link
US (2) US20040082666A1 (enExample)
EP (1) EP1379492B1 (enExample)
JP (1) JP2004525912A (enExample)
KR (1) KR20030092012A (enExample)
CN (1) CN1229331C (enExample)
AP (1) AP2003002855A0 (enExample)
AT (2) ATE396170T1 (enExample)
AU (1) AU2002245385B2 (enExample)
BR (1) BR0207716A (enExample)
CA (1) CA2440161A1 (enExample)
CH (1) CH695982A5 (enExample)
CZ (1) CZ20032380A3 (enExample)
DE (1) DE60226715D1 (enExample)
DK (1) DK200301267A (enExample)
EA (1) EA005768B1 (enExample)
EC (1) ECSP034760A (enExample)
EE (1) EE200300419A (enExample)
ES (2) ES2201942B2 (enExample)
FI (1) FI20031191A7 (enExample)
GB (1) GB2389851B (enExample)
HR (1) HRP20030710A2 (enExample)
HU (1) HUP0303341A3 (enExample)
IL (1) IL157779A0 (enExample)
LT (1) LT5143B (enExample)
LU (1) LU91038B1 (enExample)
LV (1) LV13119B (enExample)
NO (1) NO20033921L (enExample)
NZ (1) NZ527431A (enExample)
OA (1) OA12494A (enExample)
PL (1) PL363840A1 (enExample)
SE (1) SE526598C2 (enExample)
SK (1) SK10632003A3 (enExample)
TR (1) TR200705146T1 (enExample)
WO (1) WO2002070457A1 (enExample)
ZA (1) ZA200306882B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229331C (zh) * 2001-03-06 2005-11-30 伊莱利利公司 一元胺吸收的抑制剂
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するための方法及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
ATE309196T1 (de) 1999-04-09 2005-11-15 Lilly Co Eli Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
CN1229331C (zh) * 2001-03-06 2005-11-30 伊莱利利公司 一元胺吸收的抑制剂

Also Published As

Publication number Publication date
KR20030092012A (ko) 2003-12-03
FI20031191L (fi) 2003-08-25
ATA90422002A (de) 2006-01-15
ATE396170T1 (de) 2008-06-15
US20040082666A1 (en) 2004-04-29
NO20033921D0 (no) 2003-09-04
IL157779A0 (en) 2004-03-28
ES2201942B2 (es) 2004-12-16
SE526598C2 (sv) 2005-10-18
LV13119B (en) 2004-06-20
EE200300419A (et) 2004-02-16
HUP0303341A2 (hu) 2004-01-28
CZ20032380A3 (en) 2004-03-17
AP2003002855A0 (en) 2003-08-20
NO20033921L (no) 2003-11-05
ZA200306882B (en) 2004-12-03
DK200301267A (da) 2003-11-06
EA005768B1 (ru) 2005-06-30
AT414238B (de) 2006-10-15
GB0323169D0 (en) 2003-11-05
US20050209341A1 (en) 2005-09-22
EA200300978A1 (ru) 2004-02-26
HRP20030710A2 (en) 2004-08-31
HUP0303341A3 (en) 2007-03-28
GB2389851B (en) 2005-05-25
NZ527431A (en) 2005-05-27
DE60226715D1 (de) 2008-07-03
JP2004525912A (ja) 2004-08-26
EP1379492A1 (en) 2004-01-14
CA2440161A1 (en) 2002-09-12
WO2002070457A1 (en) 2002-09-12
PL363840A1 (pl) 2004-11-29
LT2003075A (en) 2004-03-25
LU91038B1 (fr) 2003-09-11
US7384983B2 (en) 2008-06-10
OA12494A (en) 2006-05-24
ECSP034760A (es) 2003-10-28
CH695982A5 (de) 2006-11-15
WO2002070457A8 (en) 2004-06-03
SE0302361D0 (sv) 2003-09-03
GB2389851A (en) 2003-12-24
SE0302361L (sv) 2003-09-03
FI20031191A7 (fi) 2003-08-25
ES2305221T3 (es) 2008-11-01
SK10632003A3 (sk) 2004-06-08
CN1229331C (zh) 2005-11-30
EP1379492B1 (en) 2008-05-21
AU2002245385B2 (en) 2007-01-18
LT5143B (lt) 2004-06-25
CN1494526A (zh) 2004-05-05
ES2201942A1 (es) 2004-03-16
BR0207716A (pt) 2004-03-23

Similar Documents

Publication Publication Date Title
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
DK1355889T3 (da) Substituerede triazoldiaminderivater som kinaseinhibitorer
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
EA200802365A1 (ru) Аминометилзамещенные тетрациклиновые соединения
DE60007095T2 (de) Calanolide zur hemmung von btk
ECSP034600A (es) Compuestos de lactama
MY136892A (en) Deacetylase inhibitors
UY26970A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
DE60204701D1 (de) Tricyclische imidazopyridine
BR0307017A (pt) agentes hipnóticos sedativos de ação rápida para anestesia e sedação
TR200705146T1 (tr) Monoamin Yükselmesinin Engellenmesi
SE0301650D0 (sv) Novel compounds
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
DE60127131D1 (de) Tricyclische imidazopyridine
WO2005041904A3 (en) Inhibitors of coronavirus protease and methods of use thereof
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
ATE418613T1 (de) Antimikrobielle zusammensetzungen
YU83903A (sh) Farmaceutske kombinacije zasnovane na derivatima piridoindolona
DK1144348T3 (da) LTA4-hydrolaseinhibitorer
DE60220504D1 (en) Tryptasehemmer
WO2005041894A3 (en) Compositions and methods for treating, preventing, reversing and inhibiting pain